Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of the stock remained 30.44million shares. The beta of the stock remained 0.73. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Merck & Co. Inc. (NYSE:MRK) will receive at least $600 million in a deal with Japanese drugmaker Santen Pharmaceutical Co. for the purchase of Merck & Co. Inc. (NYSE:MRK) eye care products in several markets. The Whitehouse Station, N.J., drugmaker said the deal was another step in its push to sharpen its commercial focus. Merck & Co. Inc. (NYSE:MRK) also recently announced that it had agreed to sell its consumer health business to Germany’s Bayer AG for $14.2 billion. That includes Claritin allergy pills, Coppertone sun-care line, and Dr. Scholl’s foot-care products. Merck & Co., Inc. (NYSE:MRK) rose 0.83 percent to $55.75 Tuesday on volume of 8.96million shares. The intra-day range of the stock was $55.20 to $56.06. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $163.94Billion.

Gilead Sciences Inc. (NASDAQ:GILD) said a Phase 2 study showed that an investigational combination of ranolazine and low-dose dronedarone reduced atrial fibrillation burden. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on May 13, 2014 reported a decrease of -0.06% to the closing price of $80.30. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $123.32billion. The overall volume in the last trading session was 8.51million shares. In its share capital, GILD has 1.54billion outstanding shares.

MannKind Corporation (NASDAQ:MNKD) reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. The net loss applicable to common stockholders for the first quarter of 2014 was $52.1 million, or $0.14 per share based on 368.8 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $41.0 million, or $0.15 per share based on 280.1 million weighted average shares outstanding for the first quarter of 2013. On Tuesday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 3.95% to close the day at $6.58. Company monthly performance is recorded as 2.65%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 15.64%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone